Ophthalmology

Experts share their real-world experience with aflibercept 8 mg, comparing it to its predecessor, aflibercept 2 mg.

Adults with strabismus in a diverse nationwide cohort were approximately 2 to 3 times more likely to experience mental health conditions.

National data show older Americans with vision impairment were less likely to have access to digital technology than counterparts without impairments.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our March 2024 ophthalmology month in review features a recap of the latest news from the ophthalmic pipeline.

The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.

Positive phase 2 results from NEPTUNE represent the best treatment failure rates observed among active studies in non-infectious uveitis.

In a systematic review and meta-analysis of available data, lotilaner ophthalmic solutions outperformed placebo, with few side effects, in treating Demodex blepharitis.

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

NCX 470 0.1% eye drops reduced IOP more than latanoprost in individuals with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc trial.

Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.

A cohort analysis in the UK observed no significant association between sildenafil use and AMD prevention in men with erectile dysfunction.

A post-hoc analysis of the Ocular Hypertension Treatment Study shows the inclusion of a PRS improved the prediction of POAG onset in patients with ocular hypertension.

Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.

Nesvategrast was safe and well tolerated but did not exhibit a statistically significant impact on the severity or progression of diabetic retinopathy in the phase 2 DR:EAM trial.

Study links childhood amblyopia with increased risk of cardiometabolic dysfunction in adulthood.

A water-free cyclosporine ophthalmic solution (SHR8028) more effectively improved total corneal fluorescein staining versus vehicle, but showed no superiority in dryness score, in phase 3 findings.

Published one-year results from PULSAR and PHOTON show extended dosing regimens with aflibercept 8 mg were non-inferior to aflibercept 2 mg for treating wet AMD and DME.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.

People of increasing age and worse socioeconomic status were more likely to be unwilling-in-principle to participate in home-monitoring vision tests.

Clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain marks the first new steroid in the ophthalmic market in over 15 years.

A secondary analysis of cross-sectional data found that serum albumin levels negatively correlated with the prevalence of diabetic retinopathy.

Our February 2024 ophthalmology month-in-review features an in-depth look into global vision loss rates, a new clinical quiz on AAO guidelines, and two episodes of our flagship ophthalmology podcast, New Insight with Veeral Sheth, MD.

The newest version of ChatGPT accurately responded to most multiple-choice questions on ophthalmic cases but performed better on non-image–based questions.

The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations in ophthalmology research.

Brassica Pharma Pvt. Ltd. is voluntarily recalling eye ointment products with expiration dates from February 2024 to September 2025.